CIP2A and non-small cell lung carcinoma: This indicates that they may act via such mechanisms as the cancerous inhibitor of protein phosphatase 2A (CIP2A) pathway, through which Erlotinib induces apoptosis in NSCLC cells that do not have EGFR mutations; however, this should be investigated further (Wang et al., 2014).